Browse diseases

…opposed to 18/37 (49%) of FAPI-positive patients.Conclusions In psoriasis patients with arthralgia, 68Ga-FAPI uptake, indicating fibrobla…

…mes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about ps…

…lerosis(MS) and psoriasis. We propose that the co-occurrence of psoriasis and MS (PsoMS) represents a distinct clinical variant of MS,cha…

…m 5.3% to 17.9% across definitions. In matched comparisons with atopic dermatitis, only a few and inconsistent differences were observed. In cont…

…, a selective IL-23 inhibitor, was administered at the standard psoriasis regimen. Over 12 months, the patient achieved clinical, endosco…

…risankizumab is administered at the first sign of self-assessed psoriasis recurrence, (2) therapeutic drug monitoring-guided treatment, w…

…ions IL-23i therapy was associated with lower risks of incident liver disease and related outcomes in psoriasis, suggesting biologic selectio…

…Introduction Psoriasis is a chronic inflammatory skin disease that significantly impac…

…Introduction The clinical course of psoriasis is characterised by marked heterogeneity. Despite the availabil…

…ated variables were selected and included in the path analysis. Psoriasis (OR 1.105, 95% CI 1.058 to 1.156) and Tinea pedis (OR 1.067, 95…

…median (IQR) Dermatology Life Quality Index was 7.0 (2.0–14.0). Psoriatic arthritis was present in 20.2% of the patients and nail psoriasis in 36.7…

…sis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD), and ulcerative colitis (UC).To evaluate treatment in a real-world setting, drug persis…